A prospective single-centre observational series of omalizumab in paediatric chronic inducible urticaria, reported by Inna Larkova with Valeryi Mukhortykh, Diana Zenkevich and Vera Revyakina. Federal

An assessment of where endotype-directed prescribing now stands following two regulatory approvals, presented by Martin Metz (Berlin, Germany), who also co-chaired the session with Ana

An expert overview of pathomechanism and the emerging therapeutic pipeline, delivered by Ana Maria Giménez-Arnau (Barcelona, Spain), who also co-chaired the session with Martin Metz,

An expert overview of pathomechanism and the emerging therapeutic pipeline, delivered by Ana Maria Giménez-Arnau (Barcelona, Spain), who also co-chaired the session with Martin Metz,

SETTING THE SCENE JAK1 inhibition in AD has been validated at the clinical endpoint level, but the cellular mechanism in the skin itself remains incompletely

SETTING THE SCENE Both JAK1 inhibitors and dupilumab produce impressive efficacy on treatment, but what happens after planned or forced discontinuation remains incompletely characterised. The

SETTING THE SCENE Facial AD in children with skin of colour is a sensitive therapeutic niche: topical corticosteroids are often avoided due to pigmentary and

SETTING THE SCENE The 2% crisaborole formulation is one of the main non-steroidal options for pediatric mild-to-moderate AD, but its stand-alone performance leaves room for

In a study at the 33rd EADV Congress 2024, on cutaneous squamous cell carcinoma (cSCC), leading experts from across Europe and the United States convened

This session was presented at the 33rd EADV Congress at Amsterdam by Drs Elisa Crystal Sanchez Moreno et al from Dermacenter, Jalisco, Mexico A groundbreaking